KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial.

Yongquan Gu, Shijun Cui, Changjian Liu, Jichun Zhao, Ming Li, Yiqing Li, Xinglong Yang, Bonan Lv, Mingzhang Li, Wenguang Zhao, Wei Guo, Jianhua Huang, Wen Huang, Zhenming Qiu, Jun Zhao, Ping Yin, Tingting Qin, Dan Zhu, Wenjie Sun, Keyun Ren, Yuxin Lu, Xiaochen Cheng, Li Du, Fengjun Xiao, Qinglin Zhang, Zuze Wu

Hum Gene Ther 32(15-16) 839-849

PMID33726499
PMCID-
DOI10.1089/hum.2020.290
发表日期2021-03-17
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

This phase II clinical trial investigated the efficacy and safety of intramuscular injection of plasmid pUDK-HGF, which encodes the human hepatocyte growth factor gene in patients with critical limb ischemia. Resting pain patients (n = 119) and patients with leg ulcers (n = 121) were enrolled as two cohorts and randomized to receive pUDK-HGF treatment on days 0, 14, and 28. In the resting pain cohort, the proportion of patients with complete pain relief on day 180 after receiving pUDK-HGF injection, as the primary outcome, was significantly higher than that of the placebo group on the same day (p = 0.0148). More responders with >50% pain reduction were also observed in the pUDK-HGF groups than in the placebo groups (p = 0.0168). In the ulcer cohort of patients, pUDK-HGF treatment tended to be superior to the placebo in the percentage of patients with both complete ulcer healing and >50% ulcer healing. No significant differences in the incidence of adverse events (AEs) or serious AEs were observed among the groups. The mid-dose pUDK-HGF (6 mg) was the most efficacious, and is therefore an appropriate dose for use in a phase III clinical trial. This study was approved by the China Food and Drug Administration (2013L00637), China Clinical Trial Registry URL: www.chinadrugtrials.org.cn. Unique Identifier: 20130378.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。